- Home
- SXTP vs XRTX Comparison
SXTP vs XRTX Comparison
Compare SXTP & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SXTP | XRTX |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | Canada |
| Employees | 3 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 2.7M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | SXTP | XRTX |
|---|---|---|
| Price | $2.05 | $0.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $17.60 | N/A |
| AVG Volume (30 Days) | 46.6K | ★ 109.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $146.28 | N/A |
| Revenue Next Year | $24.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.37 |
| 52 Week High | $8.62 | $1.41 |
Technical Indicators
Market Signals| Indicator | SXTP | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.03 | 52.08 |
| Support Level | $1.99 | $0.38 |
| Resistance Level | $2.58 | $0.58 |
| Average True Range (ATR) | 0.25 | 0.04 |
| MACD | -0.21 | 0.01 |
| Stochastic Oscillator | 1.27 | 100.00 |
Price Performance
Historical ComparisonAbout SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.